There's a scene in Gattaca where Ethan Hawke's character — genetically "inferior" — swims against his perfect brother in open water and wins. When asked how, he answers: "I never saved anything for the swim back."

That line popped into my head watching BioVie Inc.'s (BIVI) presentation last Wednesday, March 4th. A NASDAQ small cap, led by a Vietnamese-American CEO named Cuong Do, who basically got on stage and said: "Our drug improves Parkinson's, Alzheimer's, reduces inflammation, fights insulin resistance, and as a bonus slows down biological aging."

Holy shit. All that in one pill?

What BioVie Is Actually Doing

Let's skim the foam off the beer and look at the liquid underneath.

BioVie's main asset is Bezisterim (formerly called NE3107). It's not a conventional drug — it's classified as an inflammation modulator. In practice, it acts on the production of TNF-alpha, an inflammatory cytokine that plays a starring role in neurodegenerative diseases, insulin resistance, and yes, the wreckage Long COVID left in the bodies of millions of people.

According to Cuong Do on the call:

  • Parkinson's patients treated with Bezisterim showed improvement in motor control.
  • Alzheimer's patients showed cognitive and functional improvement.
  • In both groups, there was a reduction in DNA methylation levels — which, in plain English, means the body's biological clock slowed down.

Read that right? We're talking about a potential modulator of the aging process.

If you're thinking "this sounds too good to be true," congrats. Your bullshit detector is properly calibrated. But hold on.

Why This Isn't (Necessarily) Wellness Guru Talk

Here's where things get interesting for anyone with skin in the game.

First: BioVie isn't promising a cure. They're reporting clinical data from real trials. There's a massive difference between a company publishing clinical trial data and some health coach on Instagram selling hibiscus tea as "anti-aging."

Second: the mechanism of action — modulating TNF-alpha — is established science. Drugs like Humira (adalimumab) already rake in tens of billions doing something similar, but for rheumatoid arthritis and autoimmune diseases. BioVie's play is pointing that weapon at the brain.

Third: DNA methylation as a biomarker for aging is a real frontier of science. This isn't fiction. Steve Horvath's "epigenetic clock" is accepted by the scientific community. If Bezisterim actually modulates this, we're looking at something with massive implications.

The Other Side of the Coin — Because I'm Not in the Business of Selling Dreams

Now, the cold shower.

BioVie is a micro cap. Ticker BIVI on NASDAQ. That means low liquidity, roller-coaster volatility, and dilution risk that would make the Titanic look like a paper boat.

We're still in clinical phase. The road between "promising trial data" and "FDA-approved drug generating revenue" is long, expensive, and littered with corporate corpses. For every Moderna that made it, there are 500 biotechs that turned to dust.

And there's the elephant in the room: Long COVID as a therapeutic indication is politically loaded. Part of the medical community still debates whether the condition even exists as a distinct clinical entity. Navigating that regulatory minefield won't be trivial.

As Nassim Taleb would say: the problem isn't what you know, it's what you don't know you don't know.

What Does a Smart Investor Do With This?

Doesn't buy blindly. Doesn't ignore it blindly.

BioVie is playing in a space where, if they nail it, the upside is insane — we're talking about combined addressable markets (Parkinson's + Alzheimer's + Long COVID) that exceed hundreds of billions of dollars. But the "if" here is Grand Canyon-sized.

This is intelligent position sizing territory. The kind of bet you make with money you can afford to lose 100%, knowing the asymmetric payoff justifies the risk. Ed Thorp would do it. Buffett probably wouldn't — and that's fine.

The question that remains is: do you have the stomach to hold a biotech micro cap in the middle of a clinical phase, knowing it could go to zero OR multiply 20x?

Because in the market, just like in Gattaca's ocean, the ones who save energy for the swim back usually never get there.